Foundayo, FDA-approved April 1, 2026, is the first GLP-1 pill that can be taken any time of day with no food or water timing restrictions — solving the biggest practical complaint about oral semaglutide. Here's the full breakdown of results, cost, and how it stacks up.
What just happened: On April 1, 2026, the FDA approved Foundayo (orforglipron) — Eli Lilly's new once-daily oral GLP-1 medication for weight loss. It is the second oral GLP-1 ever approved (after oral Wegovy in December 2025) and the first that can be taken at any time of day, with or without food, with no water restrictions.
Why this matters more than it sounds
If you've looked into oral semaglutide (Rybelsus/oral Wegovy), you already know the catch: it must be taken first thing in the morning on a completely empty stomach with no more than 4oz of water, then you wait 30 minutes before eating, drinking anything else, or taking other oral medications. Miss that window and absorption drops significantly.
Foundayo eliminates that problem entirely. It uses a different chemical approach — orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist, rather than a peptide requiring an absorption enhancer the way oral semaglutide does. That structural difference is exactly why it doesn't need the strict dosing window.
27.3 lbs
Average weight lost at highest dose, 72-week trial
~11–12.4% body weight
$149
Self-pay starting price per month (lowest dose)
Via LillyDirect
$25
Monthly cost with the Foundayo savings card (commercial insurance)
If eligible
How Foundayo compares to other GLP-1 options
| Factor | Foundayo | Oral Wegovy (semaglutide) | Injectable tirzepatide |
|---|
| Form | Once-daily pill | Once-daily pill | Weekly injection |
| Food/water restriction | None — any time of day | Strict empty-stomach AM window | None |
| Avg weight loss (highest dose) | ~11–12.4% | Similar range, slightly lower bioavailability profile | ~22% |
| FDA approval date | April 2026 | December 2025 | 2022 |
| Self-pay starting price | $149/mo | $149–299/mo | $125–399/mo (compounded) |
| Cardiovascular trial data | Positive April 2026 readout | Limited so far | Ongoing (SURMOUNT-MMO) |
Does Foundayo work as well as injections?
At its highest dose, Foundayo produced approximately 11–12.4% average body weight loss over 72 weeks — meaningful, real results, but notably below tirzepatide's ~22% average from the SURMOUNT injectable trials. No head-to-head trial between Foundayo and injectable tirzepatide has been conducted, so this is an indirect comparison across separate trial populations, not a true apples-to-apples result.
For patients specifically prioritizing the convenience of a pill with zero dosing restrictions over maximum possible weight loss, Foundayo is a genuinely strong option. For patients prioritizing the single highest weight loss outcome available, injectable tirzepatide remains the stronger choice based on current trial data.
Medicare GLP-1 Bridge coverage
Foundayo is included in the Medicare GLP-1 Bridge program. Starting July 1, 2026, eligible Medicare Part D beneficiaries may access Foundayo for a flat $50/month copay — the same Bridge program that covers Wegovy and Zepbound. See our
full Medicare GLP-1 Bridge eligibility guide for exact BMI and clinical criteria.
Who should consider Foundayo
- People who tried oral Wegovy and found the dosing window impractical — Foundayo directly solves that specific complaint.
- People with needle aversion who still want strong GLP-1 results — a genuine non-injectable option with real trial data behind it, not a compounded workaround.
- Medicare beneficiaries who qualify under the Bridge program and want pill form over injection.
- People newly diagnosed as overweight/obese looking for the lowest-friction entry point into GLP-1 therapy.
Who should consider injectable tirzepatide instead
- Patients prioritizing maximum weight loss outcome over delivery convenience
- Patients with significant insulin resistance, where tirzepatide's dual GLP-1/GIP mechanism has a clearer clinical rationale
- Patients for whom cost is the primary driver — compounded tirzepatide can be cheaper than Foundayo's self-pay price at some providers
Side effects and safety
Foundayo's side effect profile is similar to other GLP-1 medications: nausea, diarrhea, constipation, and stomach pain, typically most pronounced during dose escalation. It carries a boxed warning regarding a potential risk of thyroid tumors, consistent with other GLP-1 class medications, and is not recommended for those with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. As with all GLP-1 medications, discontinue and consult a physician immediately if pregnancy occurs, and be aware it may reduce the effectiveness of oral contraceptives.
✅ The bottom line
Foundayo is a genuine advance for oral GLP-1 therapy — it solves the single biggest practical complaint about oral semaglutide while delivering real, FDA-validated weight loss results. It's not as powerful as injectable tirzepatide on paper, but for the right patient — someone who wants pill convenience without the strict dosing ritual — it's the strongest oral option available as of mid-2026.
Considering your GLP-1 options?
DirectMeds offers physician-supervised compounded semaglutide and tirzepatide injections from $99-149/month. Our free Treatment Optimizer can help you compare your options based on your specific situation.
Run the Treatment Optimizer →
Frequently asked questions
What is Foundayo and how is it different from oral Wegovy?
Foundayo (orforglipron) is a new once-daily oral GLP-1 medication approved by the FDA on April 1, 2026. Unlike oral Wegovy (semaglutide), which must be taken on an empty stomach first thing in the morning with strict water and timing restrictions, Foundayo can be taken at any time of day with or without food. This is because Foundayo is a small-molecule, non-peptide GLP-1 agonist, while oral semaglutide is a peptide requiring a special absorption enhancer that necessitates strict dosing conditions.
How much weight can you lose on Foundayo?
In clinical trials, participants on the highest dose of Foundayo lost an average of approximately 27.3 pounds, or roughly 11-12.4% of body weight, over 72 weeks. This is meaningful weight loss but generally lower than the approximately 22% average seen with injectable tirzepatide in the SURMOUNT trials. No direct head-to-head trial between Foundayo and tirzepatide has been conducted.
How much does Foundayo cost?
Self-pay patients can access Foundayo starting at $149 per month for the lowest dose through LillyDirect. Patients with eligible commercial insurance may pay as little as $25 per month using the Foundayo savings card. Eligible Medicare Part D beneficiaries may be able to access Foundayo for $50 per month starting July 1, 2026 through the Medicare GLP-1 Bridge program.
Is Foundayo covered by Medicare?
Foundayo is included in the Medicare GLP-1 Bridge program, a temporary CMS demonstration that began July 1, 2026. Eligible Medicare Part D beneficiaries who meet BMI and clinical criteria can access Foundayo for a flat $50 monthly copay. See our complete Medicare GLP-1 Bridge eligibility guide for the exact qualifying criteria.